{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Mixed+Cell+Adenocarcinoma&page=2", "query": { "condition": "Ovarian Mixed Cell Adenocarcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Mixed+Cell+Adenocarcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T15:22:38.118Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00939809", "title": "A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Carcinoma", "Malignant Ovarian Mixed Epithelial Tumor", "Ovarian Brenner Tumor", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Cystadenocarcinoma", "Ovarian Serous Cystadenocarcinoma", "Primary Peritoneal Carcinoma", "Recurrent Ovarian Carcinoma", "Undifferentiated Ovarian Carcinoma" ], "interventions": [ { "name": "Urokinase-Derived Peptide A6", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 31, "start_date": "2009-07", "completion_date": null, "has_results": true, "last_update_posted_date": "2019-01-15", "last_synced_at": "2026-06-10T15:22:38.118Z", "location_count": 16, "location_summary": "Augusta, Georgia • Iowa City, Iowa • Omaha, Nebraska + 11 more", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Stony Brook", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00939809" }, { "nct_id": "NCT04681248", "title": "Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Esophageal Neoplasm", "Adenocarcinoma of the Gastroesophageal Junction", "GastroEsophageal Cancer", "Squamous Cell Carcinoma", "Gastric Adenocarcinoma", "Endometrial Cancer", "Uterine Cancer", "Ovarian Cancer", "Carcinosarcoma", "Gastric Cancer" ], "interventions": [ { "name": "DKN-01", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Leap Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2025-08-03", "last_synced_at": "2026-06-10T15:22:38.118Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Madison", "state": "Wisconsin" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04681248" }, { "nct_id": "NCT00788125", "title": "Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Extragonadal Germ Cell Tumor", "Kidney Cancer", "Liver Cancer", "Lymphoma", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Testicular Germ Cell Tumor", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "dasatinib", "type": "DRUG" }, { "name": "etoposide phosphate", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "microarray analysis", "type": "GENETIC" }, { "name": "western blotting", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 7, "start_date": "2008-09-03", "completion_date": "2022-07-30", "has_results": true, "last_update_posted_date": "2023-07-14", "last_synced_at": "2026-06-10T15:22:38.118Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00788125" }, { "nct_id": "NCT00331422", "title": "Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Peritoneal Cavity Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "cytoreductive surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 7, "start_date": "2005-10", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-06-10T15:22:38.118Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00331422" }, { "nct_id": "NCT01666444", "title": "VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "pegylated liposomal doxorubicin (PLD)", "type": "DRUG" }, { "name": "VTX-2337", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 297, "start_date": "2012-10-31", "completion_date": "2016-07-31", "has_results": true, "last_update_posted_date": "2019-09-26", "last_synced_at": "2026-06-10T15:22:38.118Z", "location_count": 136, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Burbank, California + 104 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burbank", "state": "California" }, { "city": "Hayward", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01666444" }, { "nct_id": "NCT02498665", "title": "A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndromes", "Glioblastoma Multiforme", "Melanoma", "Non-Small Cell Lung Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Sarcoma", "Renal Cell Carcinoma" ], "interventions": [ { "name": "DSP-7888 Dosing Emulsion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2015-11", "completion_date": "2018-09", "has_results": false, "last_update_posted_date": "2023-11-14", "last_synced_at": "2026-06-10T15:22:38.118Z", "location_count": 8, "location_summary": "Denver, Colorado • Atlanta, Georgia • Lafayette, Indiana + 5 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Austin", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02498665" }, { "nct_id": "NCT05461430", "title": "Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pleural Effusion, Malignant", "Ascites, Malignant", "Carcinoma", "Carcinoma, Hepatocellular", "Carcinoma, Renal Cell", "Carcinoma, Renal", "Carcinoma, Small Cell", "Carcinoma, Non-Small-Cell Lung", "Carcinoma, Pancreatic Ductal", "Carcinoma, Neuroendocrine", "Carcinoma, Thymic", "Carcinoma, Pancreatic", "Carcinoma Breast", "Carcinoma, Ovarian", "Carcinoma Bladder", "Carcinoma of Unknown Primary", "Carcinoma of the Head and Neck", "Carcinoma of the Oropharynx", "Carcinoma of the Larynx", "Carcinoma of the Bladder", "Carcinoma of Esophagus", "Carcinoma of the Nasopharynx", "Carcinoma of the Penis", "Carcinoma of the Cervix", "Carcinoma of the Anus", "Carcinoma of the Vulva", "Carcinoma of the Appendix", "Carcinoma of the Oral Cavity", "Cholangiocarcinoma", "Melanoma", "Mesothelioma", "Pancreatic Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Travera Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2022-07-15", "completion_date": "2026-03-23", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-06-10T15:22:38.118Z", "location_count": 1, "location_summary": "Oakland, California", "locations": [ { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05461430" }, { "nct_id": "NCT00899093", "title": "YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Fallopian Tube Adenocarcinoma", "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Malignant Ovarian Brenner Tumor", "Malignant Ovarian Clear Cell Tumor", "Malignant Ovarian Endometrioid Tumor", "Malignant Ovarian Mixed Epithelial Tumor", "Malignant Ovarian Mucinous Tumor", "Malignant Ovarian Neoplasm", "Malignant Ovarian Serous Tumor", "Malignant Ovarian Transitional Cell Tumor", "Ovarian Adenocarcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Primary Peritoneal Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Primary Peritoneal Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Primary Peritoneal Cancer", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Cancer", "Stage IV Primary Peritoneal Cancer", "Undifferentiated Fallopian Tube Carcinoma", "Undifferentiated Ovarian Carcinoma" ], "interventions": [ { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 2500, "start_date": "2007-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2018-05-22", "last_synced_at": "2026-06-10T15:22:38.118Z", "location_count": 131, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 99 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Burbank", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899093" }, { "nct_id": "NCT05544929", "title": "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Cutaneous Melanoma", "Carcinoma, Renal Cell", "Carcinoma, Ovarian Epithelial", "Nasopharyngeal Carcinoma", "Carcinoma, Thymic", "Anal Cancer", "Mesothelioma", "Esophagogastric Cancer", "High Microsatellite Instability Colorectal Carcinoma", "Squamous Cell Carcinoma of Head and Neck", "Triple Negative Breast Neoplasms" ], "interventions": [ { "name": "KFA115", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 126, "start_date": "2022-10-26", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-06-10T15:22:38.118Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05544929" }, { "nct_id": "NCT03660826", "title": "Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Endometrioid Adenocarcinoma", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspirate", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Cediranib Maleate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 288, "start_date": "2018-09-27", "completion_date": "2027-03-04", "has_results": true, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-06-10T15:22:38.118Z", "location_count": 762, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 482 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03660826" } ] }